RBC Life Sciences (RBCL) Stock Price, News & Analysis

Company Overview

RBC Life Sciences Ltd. is a Canadian-based holding company focused on the acquisition, development and commercialization of innovative life sciences technologies. Through strategic investments and partnerships, the company assembles a diversified portfolio of early- to mid-stage enterprises specializing in diagnostic screening, therapeutic platforms and natural health products. Its overarching goal is to accelerate the path from research and development to clinical application across a range of wellness and disease-management segments.

Among its core assets, RBC Life Sciences holds a majority interest in Cortical Diagnostics Inc., which has developed a patented, tablet-based memory assessment tool designed for early detection of neurodegenerative conditions such as Alzheimer’s disease. The company also maintains ownership of Sigyn Therapeutics, a preclinical-stage business advancing novel antibody-based treatments for autoimmune and neurological disorders. Through these subsidiaries, RBC Life Sciences leverages a combination of proprietary technology, clinical partnerships and regulatory expertise to address significant unmet needs in patient care.

In addition to its diagnostic and therapeutic ventures, RBC Life Sciences pursues complementary opportunities in the natural health sector, working with research labs and manufacturing partners to bring botanical and nutraceutical formulations to market. These products are distributed primarily in North America and Europe, where the company collaborates with academic institutions and health-care providers to validate efficacy and ensure compliance with local regulatory requirements. This multi-pronged approach allows RBC Life Sciences to mitigate risk while maintaining exposure to high-growth segments of the healthcare industry.

Founded in the early 2000s and headquartered in Victoria, British Columbia, RBC Life Sciences is led by a management team with extensive expertise in biotech commercialization, regulatory affairs and finance. Under the direction of CEO Steven Siegel and Chief Scientific Officer Dr. Matthew Streck, the company continues to explore new partnerships and licensing arrangements. By leveraging its consolidated platform and cross-disciplinary capabilities, RBC Life Sciences aims to drive innovation and deliver long-term value for stakeholders in the dynamic life sciences market.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 1,700 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

RBCL Stock Analysis - Frequently Asked Questions

How do I buy shares of RBC Life Sciences?

Shares of RBCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of RBC Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that RBC Life Sciences investors own include NVIDIA (NVDA), Arcadis (ARCVF), AdvancePierre Foods Holdings, I (APFH), Artisan Partners Asset Management (APAM), American Superconductor (AMSC), ARCAM/SH (AMAVF) and Allison Transmission (ALSN).

Company Calendar

• Today: 7/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Wholesale
• Current Symbol: OTCMKTS:RBCL
• CIK: 830052
• Web: www.rbclifesciences.com
• Phone: (972) 893-4000
• Fax: 972-893-4111
• Employees: 89
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A